Abstract: Provided herein is an antibody-drug conjugate (ADC) especially a PEGylated mono- or bispecific antibody hydroxyl-bearing drug conjugate prepared with site-specific conjugation to provide homogeneous conjugate with high potency and low toxicity. The disclosure also relates to a method for the preparation of the antibody hydroxyl-bearing drug conjugate, a composition comprising the antibody hydroxyl-bearing drug conjugate, and the use thereof in treating diseases.

Abstract: This invention relates to multi-specific molecules, such as long acting multi-specific antibodies. Also disclosed are related methods.

Abstract: An antibody-drug conjugate (ADC) especially PEG based bispecific antibody-drug conjugate (P-BsADC) includes antigen binding domains bonding to CD47 and PD-L1. A method for the preparation of the P-BsADC, a composition including the P-BsADC, and the use thereof in treating diseases.

Abstract: The provided is a T-BsAb (T-cell-engaging bispecific antibody) with dual affinities to CD3 on T cells and CD19 on B cells and use thereof in treating autoimmune diseases. In particular, the provided is a PEGylated T-BsAb with dual affinities to CD3 and CD19 and use thereof in treating multiple sclerosis (MS) as well as other autoimmune diseases.

Abstract: Provided are bispecific molecules and, in particular, long acting bispecific T cell engagers targeting CD3 and CD47 with improved efficacy, toxic profile and therapeutic window, and methods of making and using such long acting bispecific binding molecules.

Abstract: Provided herein is an antibody-drug conjugate (ADC) especially a PEGylated mono or bispecific antibody-drug conjugate (BsADC) prepared with site-specific conjugation to provide homogeneous conjugate with high potency and low toxicity. It also relates to a method for the preparation of the ADC, a composition comprising the ADC, and the use thereof in treating diseases.

Abstract: A long acting modified T-cell engager bispecific antibody with cytokine caps that provides reduced toxicity and boosted anti-tumor activity is disclosed. Method of making the modified and cytokine capped Bi-specific T-cell engager antibody is also disclosed.

Abstract: A novel in vitro system and method for predicting the in vivo behavior, such as absorption time or mechanical strength retention, of biodegradable polymeric implants and medical devices. Data from this in vitro method are correlated to in vivo absorption data, allowing for the prediction of accurate in vivo behaviors, such as absorption times. The system uses a novel bypass loop to maintain the integrity of pH measuring devices to improve the reproducibility of data collected during in vitro testing.

Abstract: This invention relates to multi-specific molecules, such as long acting multi-specific antibodies. Also disclosed are related methods.

Abstract: This invention relates to multi-specific molecules, such as long acting multi-specific antibodies. Also disclosed are relates methods.

Abstract: A novel in vitro system and method for predicting the in vivo behavior, such as absorption time or mechanical strength retention, of biodegradable polymeric implants and medical devices. Data from this in vitro method are correlated to in vivo absorption data, allowing for the prediction of accurate in vivo behaviors, such as absorption times. The system uses a novel bypass loop to maintain the integrity of pH measuring devices to improve the reproducibility of data collected during in vitro testing.

Abstract: This invention relates to multi-specific molecules, such as long acting multi-specific antibodies. Also disclosed are relates methods.

Abstract: The present invention relates to releasable urea linker systems involving amine-containing chemical compounds and biologically active agents. In particular, the present invention relates to reversibly releasable linkers based on intramolecular cyclization-assisted releasable urea linkages to aromatic amine-containing compounds. The present invention also relates to polymeric conjugates of indolinone-based tyrosine kinase inhibitors.

Abstract: A four arm-polyethylene glycol-7-ethyl-10-hydroxycamptothecin conjugate, such as, is disclosed. Methods of making the conjugates and methods of treating mammals using the same are also disclosed.

Abstract: Methods for preparing substantially non-antigenic polymers having lone electron pair-containing moieties in high purity are disclosed. The polymers are useful as intermediates for synthesis of amine-based polymers and in the formation of activated polymers for conjugation with nucleophiles. Conjugates and methods of preparation and treatment with the conjugates are also disclosed. The resultant polymer-amines are of sufficient purity so that expensive and time consuming purification steps required for pharmaceutical grade polymers are avoided.

Abstract: The present invention is directed to cationic lipid for the delivery of oligonucleotides and methods of modulating an expression of a targeted gene using the nanoparticle compositions. In particular, the invention relates to cholesterol and its derivatives having multiple positively charged moieties via branching spacers, and nanoparticle compositions of oligonucleotides encapsulated in a mixture of a cationic lipid, a fusogenic lipid and a PEG lipid.

Abstract: The present invention relates to polymer conjugated releasable lipids and nanoparticle compositions containing the same for the delivery of nucleic acids and methods of modulating gene expression using the same. In particular, this invention relates to releasable polymeric lipids containing an acid-labile linker based on a ketal or acetal-containing linker, or an imine-containing linker.

Abstract: The present invention is directed to releasable cationic lipids and nanoparticle compositions for the delivery of nucleic acids and methods of modulating an expression of a target gene using the same. In particular, the invention relates to cationic lipids including an acid labile linker, and nanoparticle compositions containing the same.

Abstract: The present invention relates to releasable fusogenic lipids and nanoparticle compositions containing the same for the delivery of oligonucleotides and methods of modulating gene expression using the same. In particular, this invention relates to releasable fusogenic lipids containing an imine linker and a zwitterionic moiety.

Abstract: A four arm-polyethylene glycol-7-ethyl-10-hydroxycamptothecin conjugate, such as, is disclosed. Methods of making the conjugates and methods of treating mammals using the same are also disclosed.